23Andme Holding Co ( (ME) ) has released its Q3 earnings. Here is a breakdown of the information 23Andme Holding Co presented to its investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
23andMe Holding Co. is a prominent genetics-led consumer healthcare and research company committed to helping individuals access and benefit from the human genome. The firm’s recent third-quarter financial results highlight ongoing challenges, including liquidity concerns and operational setbacks. Total revenue for the quarter was $60.3 million, a notable increase from the previous year, mainly due to non-recurring research services revenue, although consumer services revenue saw a decline. Despite cost-cutting measures, including workforce reductions and the discontinuation of its Therapeutics segment, the company reported a net loss of $26.8 million, a significant improvement from last year’s loss. The company is actively seeking additional capital to bolster its financial position amid uncertainties about its future sustainability. Management remains focused on strategic measures to address financial challenges and improve 23andMe’s liquidity and operational efficiency.
